Rapid IMPROVEMENT in Nasal Congestion Seen as early as (results are descriptive, definitive conclusions cannot be made as this was a post hoc analysis; data prior to Week 24 were not multiplicity controlled)1,a
a LSM difference between DUPIXENT 300 mg Q2W + INCS (n=438) and placebo + INCS (n=286): -0.07 (95% CI: -0.13, -0.01).1,2
- Week 24 (SINUS-52): 51% improvement at Week 24 with DUPIXENT 300 mg Q2W + INCS (n=295, pooled DUPIXENT arms) (-1.25 from a baseline score of 2.46) vs 16% improvement with placebo + INCS (n=153) (-0.38 from a baseline score of 2.38) (LSM difference vs placebo: -0.87 [95% CI: -1.03, -0.71]) in SINUS-524,b
- Week 24 (SINUS-24): -1.34 improvement
in Nasal Congestion score with DUPIXENT vs -0.45 improvement with
placebo; LSM difference vs placebo: -0.89 (95% CI: -1.07,-0.71) (coprimary endpoint)4,d
bWeek 24 in SINUS-52. LSM difference between DUPIXENT 300 mg Q2W + INCS (n=295, pooled arms) and placebo + INCS (n=153): -0.87 (95% CI: -1.03, -0.71) (-1.25 from a baseline score of 2.46 vs -0.38 from a baseline score of 2.38, respectively) (P<0.0001).
cWeek 52 in SINUS-52 (key secondary endpoint). LSM difference between DUPIXENT 300 mg Q2W + INCS (n=150) and placebo + INCS (n=153): -0.98 (95% CI: -1.17, -0.79) (-1.35 from a baseline score of 2.48 vs -0.37 from a baseline score of 2.38, respectively).
dWeek 24 in SINUS-24. LSM difference between DUPIXENT 300 mg Q2W + INCS (n=143) and placebo + INCS (n=133): -0.89 (95% CI: -1.07, -0.71) (-1.34 from a baseline score of 2.26 vs -0.45 from a baseline score of 2.45, respectively).4
Nasal congestion/obstruction (NC) score (range 0-3); reduced score indicates improvement.4
All patients in the placebo and DUPIXENT arms were on a background therapy of INCS (mometasone furoate nasal spray).3
CI, confidence interval; INCS, intranasal corticosteroid; LSM, least squares mean; Q2W, once every 2 weeks.
Administration
options for patients
on DUPIXENT.